Zelda Therapeutics Ltd. announced that it has signed a distribution agreement with Health House Holdings Ltd. ("Health House"). This follows on from recent announcement regarding the intention to launch the HOPE® products in 2020 and is an important part of Zelda's commercialisation strategy as it transitions towards revenue generation. Health House is a UK-based specialist medicinal cannabis company that wholesales and distributes medicinal cannabis products in Australia and the United Kingdom to community and hospital pharmacies.

Health House has an extensive network of medicinal healthcare professionals that support and assist doctors gain with information relating to Zelda-products. Under the terms of the non-exclusive agreement, Health House will distribute Zelda-branded products in Australasia and the United Kingdom, which represent some of the world's fastest growing cannabis markets. The agreements covers the distribution of HOPE®: a family of revenue generating proprietary medicinal cannabis products that have been formulated for symptoms associated with Autism Spectrum Disorder (ASD).

Zelda will acquire HOPE® as part of the proposed merger with Ilera Therapeutics. The agreement also includes Zelda's Insomnia investigation formulation, which is intended to launch in global markets pending a positive outcome from its Phase II clinical trial, with data expected in first quarter 2020.